Valganciclovir: 5 agencies, 2002–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused valganciclovir: all 10 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 21.8 years separate the first record, 6 Dec 2002 at SMC (Scotland), from the most recent, 6 Sep 2024 at CONITEC (Brazil).
AWMSG (Wales) changed its position: restricted on 7 Sep 2011, recommended by 7 Sep 2011.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
5 distinct indication wordings are recorded for valganciclovir by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess valganciclovir, on 6 Dec 2002; CONITEC (Brazil) did not open a file until 6 Sep 2024 — an unusually long tail of 21.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed valganciclovir to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales) and SMC (Scotland).
4 of the 5 agencies here assessed valganciclovir more than once, SMC (Scotland) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed valganciclovir.
The full ledger for valganciclovir reads 6 recommended, 5 other and 4 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 6 Sep 2024 | Tratamento de infecções pelo citomegalovírus em pacientes imunossuprimidos pelo HIV. | incorporated into SUS | source |
| PHARMAC (New Zealand) | 9 Aug 2018 | Widening access - extended use after lung transplant and methylprednisolone | PTAC advice: High · decision reached | source |
| AWMSG (Wales) | 7 Sep 2011 | Licence extension for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients w… | recommended with restrictions (full) | source |
| SMC (Scotland) | 17 Jan 2011 | Prevention of cetomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from CMV-positive donor | accepted (restricted) | source |
| HAS (France) | 12 Nov 2008 | Listing (Transparency Committee) | ASMR V | source |
10 further decisions for valganciclovir, across 4 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 15 decisions for valganciclovir from 5 agencies, 2002 to 2024. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.